Develops drugs for cancer and genetic diseases.
Jun 2026Revenue $10.3M/yrExpenses $321M/yr
No trendCash runway ≈ 7 months from Jun 2026
Figures by year
When will Relay Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $10.3M and expenses $321M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $15.4M | $318M | −$303M |
| Dec 2024 | $10.0M | $382M | −$372M |
| Dec 2023 | $25.5M | $399M | −$373M |
| Dec 2022 | $1.38M | $301M | −$299M |
| Dec 2021 | $3.03M | $368M | −$365M |
| Dec 2020 | $82.7M | $138M | −$55.8M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.